Could a bone drug save hearing for brittle bone patients?
NCT ID NCT04152551
Summary
This study is testing whether a common bone-strengthening drug (bisphosphonate) can slow down hearing loss in people with Osteogenesis Imperfecta (OI), also known as brittle bone disease. It will follow 100 adults and children with OI for about 5 years to see if the drug helps preserve their hearing. The goal is to find a new way to manage this specific type of hearing loss that often starts early in life for people with OI.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOGENESIS IMPERFECTA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital for Special Surgery
RECRUITINGNew York, New York, 10021, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.